Controlled Trial Evaluating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The second round of late-breaking clinical trials were presented with results from three studies during the Vascular InterVentional Advances Conference, VIVA23, being held Oct. 30-Nov. 2 in Las Vegas, NV. Notably, results from Abbott’s LIFE-BTK randomized clinical trial (RCT) demonstrated that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.

/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...

/PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the...

Natural remedies can do wonders in treating painful mouth ulcers, stomach inflammation, wounds, and infections. When it comes ...

Press release content from PR Newswire. The AP news staff was not involved in its creation.